Synthetic carbohydrate-binding agents neutralize SARS-CoV-2 by inhibiting binding of the spike protein to ACE2
Oscar Francesconi, Lorena Donnici, Marco Fragai, Elisa Pesce, Mauro Bombaci, Alessandra Fasciani, Lara Manganaro, Matteo Conti, Renata Grifantini, Raffaele De Francesco, Cristina Nativi, Stefano Roelens
Abstract
several variants of the spike protein. Preliminary tests indicated that the investigated CBAs interact with the spike protein rather than with ACE2. For a lead compound (IDS060), which has been selected among others for its lack of cytotoxicity, evidence of binding to the RBD of the spike protein has been found by NMR experiments, while competitive binding assays in the presence of IDS060 showed inhibition of binding of RBD to hACE2, although neutralizing activity was also observed with variants showing reduced or depleted binding.
Topics & Concepts
Plasma protein bindingChemistryGlycanVirusGlycoproteinBinding siteCytotoxicityBinding proteinBiochemistrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyBiologyCoronavirus disease 2019 (COVID-19)In vitroGeneMedicineDiseasePathologyInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchBacteriophages and microbial interactionsInfluenza Virus Research Studies